NLS Pharmaceutics announces 1-for-40 reverse share split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 25 2024
0mins
Should l Buy ?
Reverse Share Split Announcement: NLS Pharmaceutics will implement a 1-for-40 reverse share split of its common shares, effective September 27, 2024, with trading on Nasdaq starting under the existing symbol "NLSP" but with a new CUSIP Number.
Shareholder Approval and Impact: The reverse split was approved by shareholders on September 18, 2024, reducing the outstanding shares from approximately 46.88 million to about 1.17 million shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
